List of Vasostrict drug patents

Vasostrict is owned by Par Sterile Products.

Vasostrict contains Vasopressin.

Vasostrict has a total of 14 drug patents out of which 0 drug patents have expired.

Vasostrict was authorised for market use on 17 April, 2014.

Vasostrict is available in solution;intravenous dosage forms.

Vasostrict can be used as to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

The generics of Vasostrict are possible to be released after 30 January, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375478 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9744209 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9937223 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9744239 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US10010575 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9981006 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9974827 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9968649 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9962422 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9925234 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9925233 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9687526 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9750785 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

US9919026 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(12 years from now)

Drugs and Companies using VASOPRESSIN ingredient

Market Authorisation Date: 17 April, 2014

Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of VASOSTRICT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in